rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Dror Bashan

President and CEO

Company insider

Files Form 4 as: President and CEO, Protalix BioTherapeutics, Inc. (DE).

Every Form 4 they filed

In numbers

Trades disclosed
17
Buys
3
Sells
0
Bought
$294K
Sold
$0
Companies
1
Companies where not an officer
0
First trade
30 Jun 2019
Last trade
3 Sep 2026
Last filed
4 Sep 2026

Companies traded

Where they are an officer
PLX Protalix BioTherapeutics, Inc. (DE)Director, Officer · Biotechnology · last 3 Sep 20263 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
01Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
3 Sep 2026filed 4 Sep 2026PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · BiotechnologySEC FORM 4 Code A—320,000 at $0.00filing
3 Sep 2026filed 4 Sep 2026PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · BiotechnologySEC FORM 4 Code A—160,000 at $0.00filing
3 Sep 2026filed 4 Sep 2026PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · BiotechnologySEC FORM 4 Code A—320,000 at $0.00filing
3 Sep 2026filed 4 Sep 2026PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · BiotechnologySEC FORM 4 Code A—160,000 at $0.00filing
19 Dec 2025filed 23 Dec 2025PLX Protalix BioTherapeutics, Inc. (DE)BiotechnologySEC FORM 4 Bought$101K56,000 at $1.81filing
3 Sep 2025filed 4 Sep 2025PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · BiotechnologySEC FORM 4 Code A—340,000 at $0.00filing
3 Sep 2025filed 4 Sep 2025PLX Protalix BioTherapeutics, Inc. (DE)BiotechnologySEC FORM 4 Code A—195,000filing
1 Apr 2024filed 3 Apr 2024PLX Protalix BioTherapeutics, Inc. (DE)BiotechnologySEC FORM 4 Code A—263,960filing
19 Oct 2023filed 20 Oct 2023PLX Protalix BioTherapeutics, Inc. (DE)BiotechnologySEC FORM 4 Bought$68K48,387 at $1.40filing
19 Oct 2023filed 20 Oct 2023PLX Protalix BioTherapeutics, Inc. (DE)BiotechnologySEC FORM 4 Bought$23K16,129 at $1.41filing
15 Aug 2023filed 17 Aug 2023PLX Protalix BioTherapeutics, Inc. (DE)BiotechnologySEC FORM 4 Code A—800,000filing
7 Sep 2022filed 9 Sep 2022PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · BiotechnologySEC FORM 4 Code A—750,000 at $0.00filing
11 Apr 2022filed 13 Apr 2022PLX Protalix BioTherapeutics, Inc. (DE)BiotechnologySEC FORM 4 Bought$102K68,000 at $1.50filing
25 Feb 2022filed 28 Feb 2022PLX Protalix BioTherapeutics, Inc. (DE)BiotechnologySEC FORM 4 Code A—637,531filing
11 Aug 2020filed 14 Aug 2020PLX Protalix BioTherapeutics, Inc. (DE)BiotechnologySEC FORM 4 Code A—447,927filing
11 Aug 2020filed 13 Aug 2020PLX Protalix BioTherapeutics, Inc. (DE)BiotechnologySEC FORM 4 Code A—447,927filing
30 Jun 2019filed 2 Jul 2019PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · BiotechnologySEC FORM 4 Code A—1,600,000 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care3

Buys in green, sells in red, by the company’s sector.

Related people

Aharon SchwartzDirector · Director at Protalix BioTherapeutics, filing Form 4 there in the last year
Pol F. BoudesDirector · Director at Protalix BioTherapeutics, filing Form 4 there in the last year
Gwen A. MelincoffDirector · Director at Protalix BioTherapeutics, filing Form 4 there in the last year
Yaron NaosSr. VP & COO · Sr. VP & COO at Protalix BioTherapeutics, filing Form 4 there in the last year
Eliot ForsterDirector · Director at Protalix BioTherapeutics, filing Form 4 there in the last year